Unicycive Therapeutics announced the FDA has accepted the resubmission of its New Drug Application for oxylanthanum carbonate (OLC), a treatment for hyperphosphatemia in chronic kidney disease patients on dialysis. The resubmission includes new manufacturing data from a third-party vendor and sets a PDUFA target date of March 25, 2027. This acceptance follows previous FDA concerns about the original manufacturer, but no issues were raised regarding the drug's clinical or safety data. Approval of OLC could offer patients a lower pill burden option for managing phosphate levels, improving treatment adherence.
Unicycive Therapeutics' FDA acceptance of its drug resubmission offers context for readers following health sector developments. For readers following health sector stocks, here is Pluang's market snapshot as of Oct 21, 2026 18:11 WIB: out of 150 priced US health stocks, 71 rose and 67 fell. Baxter International Inc (BAX) traded at USD 25.30 with a 3.22% increase, Nuvation Bio Inc. (NUVB) rose 2.94% to USD 4.91, while BioNano Genomics Inc (BNGO) declined 2.81% to USD 1.21.
The Human Feedback Foundation, supported by RBC, has launched the Agentic AI Design Exchange, a national program aimed at helping Canadian nonprofits design, build, and deploy AI agents responsibly. Funded through RBC's Stronger Nonprofits Program, t...
Satellos Bioscience Inc., a clinical-stage company focused on treatments for degenerative muscle diseases, announced its management will participate in two investor conferences in November: the Guggenheim Healthcare Innovation Conference on Nov 9 in ...
YYForce Inc. has purchased 20 wearable data collection systems to gather real task data from hotel room service at Novotel Singapore. This project aims to record and analyze experienced staff performing tasks like bed-making, towel folding, and clean...
The global digital health and remote patient monitoring market is projected to grow from $26.8 billion in 2025 to $80.8 billion by 2031, at a compound annual growth rate of 20.2%. This growth is driven by increasing demand for chronic disease managem...
The global private credit and alternative lending market, valued at $2.31 trillion in 2026, is expected to grow at a 7.8% CAGR to reach $3.36 trillion by 2031. Recent liquidity pressures in 2025, triggered by bankruptcies and AI sector concerns, caus...
